-
Start Preamble
CFR Correction
In Title 21 of the Code of Federal Regulations, Parts 500 to 599, revised as of April 1, 2011, on page 96, in § 516.20, (b)(2) is revised to read as follows:
Content and format of a request for MUMS-drug designation.* * * * *(b) * * *
(2) The name and address of the sponsor; the name of the sponsor's primary contact person and/or permanent-resident U.S. agent including title, address, and telephone number; the established name (and proprietary name, if any) of the active pharmaceutical ingredient of the drug; and the name and address of the source Start Printed Page 18686of the active pharmaceutical ingredient of the drug.
* * * * *[FR Doc. 2012-7532 Filed 3-27-12; 8:45 am]
BILLING CODE 1505-01-D
Document Information
- Published:
- 03/28/2012
- Department:
- Food and Drug Administration
- Entry Type:
- Rule
- Document Number:
- 2012-7532
- Pages:
- 18685-18686 (2 pages)
- PDF File:
- 2012-7532.pdf
- Supporting Documents:
- » Freedom of Information Summary ANADA 200-543 Cefpodoxime Proxetil
- » Freedom of Information Summary ANADA 200-491, Loxicom (meloxicam)
- » Freedom of Information Summary ANADA 200-485, Meloxicam Injection (meloxicam)
- » Freedom of Information Summary NADA 200-496 96% Solution Growing chickens, turkeys and laying hens
- » Freedom of Information Summary NADA 200-534 Melengestrol acetate plus monensin USP plus tylosin phosphate
- » Freedom of Information Summary NADA 141-068 BAYTRIL 100 Injectable Solution
- » Freedom of Information Summary NADA 141-346 OroCAM
- » Freedom of Information Summary NADA 141-344 VERAFLOX Suspension for Cats
- » Freedom of Information Summary ANADA 200-466 SPARMECTIN Plus Clorsulon
- » Freedom of Information Summary NADA 141-342 ALFAXAN